Increasing economic and business risks will transform the global Life Sciences industry
Largest companies require most dramatic changesDOWNLOAD
Mounting pricing pressures, expiring patents, high cost of research and development and in some cases and plummeting stock prices have plagued the industry for the past decade, forcing life sciences companies to dramatically rethink their business models to survive in the next decade. To thrive in the long run, companies cannot simply depend on future returns from new products in their pipelines. As they wake up to new market realities, they must tackle their challenges and address risk in a fundamentally different way, frequently requiring significant transformation.
According to new research “The Future of Life Sciences Industries: Transformation Amid Rising Risk”, conducted by the Deloitte Life Sciences and Health Care Industry Practice Group in collaboration with The Economist Life Sciences Industries, life sciences companies are now realizing that their business models must change.
The increasing cost of innovation and the growing hurdles to gain adequate compensation for brand leading products have made businesses far more risk-averse. Executives agree that new alternatives must be considered to bridge the gap in their innovation pipelines.
Developed in collaboration with The Economist Intelligence Unit, the DTT white paper, “The Future of Life Sciences Industries: Transformation Amid Rising Risk,” (www.deloitte.com/lifesciencessurvey) is based on a global online survey of 360 senior executives in the life sciences industry conducted in 2008. The survey asked executives to predict the level of change their companies will undergo in the future to address growing risk and what areas would face the highest growth in risk. The survey also examined how companies will increase proficiency and deal with rising risks in these areas, as well as how they would manage internal and external risk.
Belgium is currently one of the “Pharma valleys” in Europe; most of the top 30 life sciences companies have set up a European Headquarter and/or some local operations on the country; three Belgian firms (UCB , Solvay Pharma and GSK Biologicals) are part of the top 30 global life sciences companies; overall, 11% Belgium’s exports are generated by life sciences firms, 5% top 100 global medicines are developed in Belgium, about 5% of the Belgian’s workforce is working for Pharmaceutical companies, and about 17,5% total employment works in R&D.
Eric Nys, Deloitte Belgium Life Sciences and Health Care Industry leader , indicates: “The presence of so many multinational life sciences companies in Belgium, the importance of their export activities from Belgium and the international nature of the industry challenges stress the need to clearly understand the global evolution of the life sciences industry, as it will undoubtedly impact the Belgium economy”.
Deloitte regularly interacts with the different stakeholders of the Life Sciences universe in Belgium (Life Sciences companies, European Union, government and other regulatory agencies, and even doctors and patients organizations), but also scrutinizes the global evolution of the life sciences industry.
According to the survey results:
“Most creative industries have encountered challenges when facing disruptive technologies”, says Eric Nys, Deloitte Belgium Life Sciences and Health Care Industry leader. “In the case of life sciences, these companies will survive and prosper by addressing new customer needs, whether economic, health or both. Companies have to be willing to move away in some cases from past things that made them great to the new realities of delivering innovative medicines and devices within the economic realities of today’s markets.”
“The results of this survey clearly indicate that life sciences companies are now realizing that their business models must change,” says Sophie Janssens, responsible for Consulting in the Life Sciences Sector of Deloitte Belgium. “The full implications of these shifts have yet to be wholly understood; however, life sciences companies may be facing the prospect of strategic transformation as an ultimatum rather than an option. They will be challenged to work together with regulators and payers over the next decade to find new approaches that work for everyone in order to thrive.”
* Of the 360 executives responding to the 2008 survey,
* Participants represented different sectors within the life sciences industry, including
* Thirty-eight percent of respondents’ organizations had annual revenue greater than US$500 million and
* 38 percent had revenues less than US$100 million.
* Board members and chief executive officers comprised 19 percent of respondents.
* Chief financial officers, chief technology officers and other C-level executives made up 12 percent of the panel.
* Senior vice presidents, vice presidents, directors, heads of business units and departments and managers made up the remainder of the respondent panel (69%).
A leading audit and consulting practice in Belgium, Deloitte offers value added services in audit, accounting, tax, consulting and corporate finance. In Belgium, Deloitte has more than 2.400 employees in over 14 offices across the country, serving national and international companies, from small and middle sized enterprises, to public sector and non-profit organisations. The turnover reached 308 million euro in the financial year 2008.
The Belgian firm is a member of the international group Deloitte Touche Tohmatsu, an organisation of independent member firms devoted to excellence in providing professional services and advice. We are focused on client service through a global strategy executed locally in over 140 countries. With access to the deep intellectual capital of approximately 165,000 people worldwide, our member firms (including their affiliates) deliver services in various professional areas covering audit, tax, consulting, and financial advisory services. Our member firms serve over one-half of the world’s largest companies, as well as large national enterprises, public institutions, and successful, fast-growing global companies. In 2008 Deloitte Touche Tohmatsu’s turnover reached over 27 billion dollars.
Deloitte Touche Tohmatsu is a Swiss Verein (association), and, as such, neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other’s acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names “Deloitte,” “Deloitte & Touche,” “Deloitte Touche Tohmatsu,” or other related names. The services described herein are provided by the member firms and not by the Deloitte Touche Tohmatsu Verein.
Deloitte developed the Managing in Uncertain Times campaign to support "the" conversation. Everyone is talking about the global economic crisis. However, as a solutions-driven business Deloitte wants to do more than just talk. Deloitte also wants to keep doing what it is good at: providing solutions and identifying opportunities. For more information on our Managing in Uncertain Times web-based solutions toolkit, visit www.deloitte.be